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Abstract
Introduction: Making fair coverage decisions by allocating limited resources implies prioritization. Given the 
pandemic, this is even more difficult, given the economic recession and the need to cope with new demands 
for health technologies, in addition to the rest of the needs of the health system. Health Technology 
Assessment and the regulation of drug prices are two strategies recommended by WHO-PAHO to increase 
the efficiency and equity of health systems. We analize the budget impact and opportunity cost of spinraza, a 
high-cost drug that would be effective in increasing the survival of patients with a rare disease named Type I 
Spinal Muscular Atrophy. In Argentina, it is covered without price regulation, paying three times more 
expensive than in Brazil, although a National Health Technology Assessment did not recommend this. 
Methods: The opportunity cost of spinraza for Spinal Muscular Atrophy is expressed as the possibility of 
purchasing mechanical respiratory assistance equipment, which has become a universal priority in the 
pandemic context. At the current sale price, and for 100 estimated patients with Type I Spinal Muscular 
Atrophy under treatment, Argentina invests in spinraza funds equivalent to those needed to buy 2 417 
respirators, with which it could have increased its installed equipment capacity by 35% at the beginning of the 
pandemic. Acceptability curves for coverage of these technologies and scenarios of potential lives saved in 
the face of different types of drug price reduction were analyzed. Discussion: Argentina, like other countries in 
the region, must redesign decision-making processes on high-cost drug coverage to ensure the efficiency, 
equity, and sustainability of the health system. The pandemic context can be an opportunity to base decisions 
on tools such as prioritization based on health technology assessment with binding recommendations, 
estimating the opportunity cost of interventions, and regulating the prices of high-cost drugs.
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Resumen
Introducción: Tomar decisiones justas de cobertura asignando recursos limitados, implica realizar una 
priorización. Ante la pandemia esto es aún más difícil, dada la recesión económica y la necesidad de hacer 
frente a nuevas demandas tecnologías sanitarias, además del resto de necesidades del sistema de salud. 
La evaluación de tecnologías sanitarias y la regulación de precios de medicamentos son dos estrategias 
recomendadas por la OMS-OPS para incrementar la eficiencia y la equidad de los sistemas de salud. Se 
analiza el impacto presupuestario y costo de oportunidad de spinraza, un medicamento de alto costo que 
sería eficaz para incrementar la sobrevida de pacientes con una enfermedad poco frecuente denominada 
Atrofia Musculo Espinal tipo I. En Argentina se cubre, sin regulación de precios, pagando un precio tres 
veces más alto que en Brasil, pese a que esto no fue recomendado por una evaluación de tecnología 
sanitaria nacional. Métodos: Se expresa el costo de oportunidad de spinraza en AME tipo I en posibilidad de 
compra de equipos de asistencia respiratoria mecánica, los cuales han pasado a representar una prioridad 
universal en el contexto de pandemia. Al precio de venta actual, y para 100 pacientes estimados con Atrofia 
Musculo Espinal tipo I en tratamiento, Argentina invierte en spinraza fondos equivalentes a los necesarios 
para comprar 2 417 respiradores, con los que podría haber incrementado su capacidad instalada de equipos 
en un 35% al inicio de la pandemia. Se analizan las curvas de aceptabilidad para cobertura de estas 
tecnologías y escenarios de potenciales vidas salvadas ante distintos tipos de reducción de precio del 
medicamento. Discusión: Argentina, como otros países de la región, debe rediseñar procesos de toma de 
decisión sobre cobertura de medicamentos de alto costo para asegurar la eficiencia, equidad y 
sustentabilidad del sistema de salud. El contexto de pandemia puede ser una oportunidad para basar las 
decisiones en herramientas como la priorización basada en evaluación de tecnologías sanitarias con 
recomendaciones vinculantes, la estimación del costo de oportunidad de las intervenciones y la regulación 
de precios de medicamentos de alto costo.
Palabras clave: dolor, neurocirugía, hospitalización, escala visual analógica, protocolos clínicos.
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Introduction
Making fair coverage decisions, allocating limited 
resources, implies prioritizing, and is a great 
challenge that attempts to address from philosophy, 
ethics and economics (1-4). Faced with this COVID 
pandemic, this may be even more difficult, since it is 
not only a health crisis, but a “total social fact, which 
convulses all social relations, and shocks all the 
actors, the institutions and values  ”(5). With a 
forecast of large economic losses (6), governments 
finance interventions designed to contain the 
pandemic, and try to slow the spread of the virus, 
avoid hospital overflow, and protect lives. This 
strategy seeks to buy time (7) for governments to 
urgently expand their capacities for intensive 
therapy, especially respiratory support for severe 
pneumonia, the only thing that has saved seriously 
ill patients from COVID-19 (8) while waiting for the 
vaccination of the population, which has little 
chance of reaching the entire population before the 
end of 2021 (9). Up to 20% of those over 80 years of 
age would progress seriously and end up requiring 
mechanical ventilation (MRA) (10). Approximately 
12% of those hospitalized for COVID-19 require 
ARM (8). In Argentina and in most of the countries of 
the region, COVID-19 cases continue to increase 
(11), while respirators are in deficit globally (12). 
Respirators are considered so important that the 
president of the United States invoked the Defense 
Production Act so that local companies increase 
their production for that country (13), and in 
Argentina similar measures were taken by 
Presidential decree so that all production local was 
bought by the state (14).
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spinraza for SMA type I expressed in prospective 
purchase capacity of MRA equipment for critical 
care in severe pneumonia caused by COVID-19 
was represented. It was chosen to exemplify with 
spinraza due to its high budgetary impact, having 
been recently evaluated by CONETEC, making 
recommendations against its coverage at current 
prices, and because these recommendations were 
not taken into account. The comparison with the 
ability to purchase respirators is based on the fact 
that this has been one of the main technologies that 
health systems went out to buy immediately in the 
face of the pandemic, exceeding the available 
supply (12) 12, thus making explicit a homogeneous 
preference for all health decision-makers. This 
comparison is arbitrary, since there are other high-
cost drugs that impact health systems, as well as 
other technologies necessary to cope with the 
pandemic. Those mentioned are selected to show 
theoretical alternatives in a budget line from the 
point of view of an impartial decision-maker who 
must prioritize public resources with a fixed budget. 
Although budgets, by their nature, must be flexible, 
and in the face of the pandemic, most countries 
authorized an increase in the budget for Health, 
they work with a fixed budget based on various 
cons iderat ions,  which inc lude economic 
contraction, inflation and the devaluation of the 
peso-dollar exchange rate (37), as well as 
advantages given by the greater simplicity for the 
analysis.
Spinraza for Spinal Muscular Atrophy
In 2019, 259 patients with different disease 
subtypes and under the responsibility of various 
funders were under treatment with spinraza (32). An 
estimated 100 patients / year with SMA type I under 
treatment with spinraza in Argentina.
In the context of a pandemic where the need for 
respirators becomes a priority for all health 
systems, indifference curves are plotted to illustrate 
the possible decisions when prioritizing between 
respirators and spinraza.
In this exercise, an annual budget set by the cost of 
spinraza -tax-free- is assumed to treat 100 patients / 
year with SMA type 1. Only SMA type 1 is 
considered, because the contrast with severe 
patients with COVID-19 implies units It requires 
equally disappointing forecasts, the interventions of 
which carry a certain likelihood of saving lives in the 
short term. Spinraza would improve MRA-free 
survival or death at 13 months with a Hazard Ratio = 
0.53, suggesting a Number Needed to Treat (NNT) 
of 3.38 patients / year (38). This survival would be 
maintained until at least 32 months of life (39). 
Based on information provided by consultation with 
various funders who are covering treatments in 
Argentina, the tax-free price of spinraza is $ 80,580 
per dose. Six doses are required in the first year, at a 
cost per patient / year of $ 483,448 and $ 
48,348,000 for the estimated 100 patients.
Respirators
In many regions of the United States, Brazil, Chile 
and Peru, the installed capacity of respirators was 
exceeded in the scenario of a COVID-19 pandemic 
(40). In Argentina, estimates of total respirators 
have been reported at 8,560 at the beginning of the 
pandemic, leading to a ratio of 25.5 respirators per 
100,000 inhabitants (41.42). Despite the fact that it 
was later significantly increased, the available 
respirators could be insufficient according to 
different scenarios of the evolution of the pandemic 
(43). Mortality of patients requiring a respirator due 
to COVID ranges from 30 to 80% (44.45). Assuming 
that all serious cases that do not access ARM die, 
and that access to critical care in Argentina reduces 
mortality to 40%, the ventilator would have an NNT 
of 1.72; In other words, for every 1.72 people with 
severe COVID-19 pneumonia who access ARM, 
one life would be saved. The median duration of 
mechanical assistance in the ICU is estimated at 10 
days (10) and, therefore, a ventilator could be used 
in 3 patients per month. For simplicity, in this 
analysis we will consider a single annual peak, 
where each ventilator would be used in only three 
patients. This simplification is conservative, since 
most predictive models show that a single short 
peak is unlikely to occur, and a second peak is 
already underway in Argentina and other countries 
in the region. The price of standard respirators 
available in the Argentine market and in the region is 
USD 20,000 per unit (46). Costs of human 
resources, inputs and indirect costs are not included 
in the analysis.
Results
Under a fixed budget, the choice to cover spinraza 
for the entire estimated population implies losing the 
opportunity to have funds to buy 2 417 extra 
respirators and thus increase Argentina's initial 
installed capacity by 35%.
Given that both technologies would have a potential 
impact on lives saved, the analysis is deepened by 
comparing spinraza and respirators, assuming a 
fixed budget and a scenario in which only these two 
technologies could be financed. In this hypothetical 
situation, if the impartial decision maker had the 
sole objective of maximizing lives saved, he could 
save more than 99% of the lives at stake by 
spending his entire budget on purchasing only 
respirators. This occurs even assuming that each 
respirator was used in only three patients, in a single 
epidemic peak, ignoring that its amortization allows 
it to be used for several years for the benefit of other 
patients with other diseases.
Neoclassical economic theory describes that a 
financier with a fixed budget, when faced with the 
possibility of incorporating different goods, will buy 
those that provide the greatest utility, until reaching 
a point where the marginal profits per monetary unit 
spent on each of the goods are equal. This funder 
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Economic context and decision-making on 
health technologies
Like many countries in the region, Argentina 
combines pre-existing difficulties with new 
challenges related to the pandemic. With a 
fragmented and segmented health system, the 
costs of new technologies are steadily increasing, 
where judicialization for coverage is increasingly 
frequent, finding a fragile balance between demand 
and coverage (15). Given the pandemic, a drop in 
GDP of 11.8% is anticipated for Argentina with a 
rebound of 4.9% in 2021 and for Peru a fall of 13.9% 
in 2020 with a recovery of 7.3% for 2021 (16). While 
urgent needs appear to face COVID, while 
continuing to meet all other health needs not related 
to COVID.
Argentina uses an explicit list of benefits, the 
Obligatory Medical Plan (PMO), as a formal 
reference for the subsector of national social 
security and prepaid medicine companies (41% of 
the population) but which is also referenced by other 
funders such as provincial social works, pensioners 
and retirees social work, and, to a certain extent, the 
public subsector (17). Two thirds of the population 
have formal coverage and the remaining third is 
served exclusively in the public subsector. Total 
investment in health is close to 10% of its GDP (18), 
despite which allocative inefficiencies persist with 
consequences for the overall equity of the system 
(19).
High-cost drugs take a growing percentage of the 
health budget in Argentina as in other countries in 
the region. In Argentina they represent 34% of the 
PMO's total drug spending while in Chile, only three 
orphan drugs prosecuted in 2018 represented 28 
times the annual per-capita budget of the Ricarte 
Soto Law for high-cost diseases (20), and in 
Colombia the coverage of high-cost drugs is 
indicated as one of the causes of the financial health 
crisis (21). In Peru, the Ministry of Health has had 
the Intangible Solidarity Health Fund (FISSAL) 
since 2002, which finances a series of high-cost 
diseases (seven types of most frequent cancers, 
the comprehensive treatment of chronic kidney 
failure and rare and orphan diseases) in people in 
poverty (22,23).
Central strategies to improve efficiency and equity 
in relation to the use of medicines are the evaluation 
of health technologies (HTS) (24) and the regulation 
of medicine prices (25). The countries of the region 
are trying to advance towards the consolidation of 
HTA processes that include evaluations of the 
economic impact and equity (26). The drug price 
regulat ion st rategy,  which has not  been 
implemented in Argentina, unlike other countries in 
the region, such as Brazil, Colombia and Uruguay 
(27), which have various experiences that have 
made it possible to improve the efficiency of their 
drug purchases. WHO-PAHO also recommends 
other strategies, including promoting competition 
either through biosimilars, parallel imports, and 
even incentives for import substitution, modification 
of procurement mechanisms including risk-sharing 
mechanisms, and aggregation of demand to 
through joint negotiation mechanisms and 
consolidated purchases (28).
While in Argentina a National Agency of HTAs still 
awaits to be law (29), the official coverage 
recommendations emanate from an interim official 
commission, the National Commission for Health 
Technology Assessment (CONETEC), created in 
2018, with the aim of “issuing recommendations on 
the incorporation, form of use, financing and / or 
policies for the coverage of health technologies […] 
of a public nature and free consultation for all actors 
in the health system, including judicial processes 
”(30). Its reports are not binding and its 
recommendations are not fully complied with, 
weakening the potential impact of this strategy (31).
This article analyzes the opportunity cost of 
covering sprinaza for Type I Muscular Atrophy 
(SMA) in Argentina. SMA is a hereditary 
neuromuscular disease characterized by the 
involvement of the cells of the anterior horn of the 
spinal cord (motor neurons), which presents with 
symmetric proximal weakness and progressive 
atrophy of the muscle groups. It is a rare disease, 
highly disabling and with high mortality in its most 
serious forms. It has an approximate incidence of 1 
in 6,000 / 10,000 live births, and is the main cause of 
infant mortality due to a genetic disease (32). Four 
forms of presentation of SMA are known, and there 
is evidence that in SMA type I, spinraza reduces 
mortality and the requirement for mechanical 
ventilatory assistance, as well as improves motor 
function, allowing the development and acquisition 
of certain skills (for example sitting, standing, or 
walking) until at least 13 months of observation. It is 
estimated that approximately 100 patients with SMA 
type I receive spinraza in Argentina (32).
Spinraza was not included in the WHO Essential 
Medicines List (33), and despite having a negative 
recommendation by CONETEC (31), it was 
included in the PMO for one year (34,35). Its 
opportunity cost is related to the purchase of 
mechanical ventilation equipment, which has 
become one of the highest priorities in effective and 
safe health technologies to face the pandemic. The 
objective of this study is to illustrate, in this way, the 
impact of high-cost drugs such as spinraza 
(Nusinersen®), and the urgent need to adopt 
strategies to improve efficiency and equity; Among 
them, base decisions on ETES and implement price 
regulation schemes. The context of a pandemic can 
become an opportunity to re-discuss health policies 
related to high-cost drugs, which put the 
sustainability of health systems at risk.
Methodology
The budgetary impact and opportunity cost of 
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spinraza for SMA type I expressed in prospective 
purchase capacity of MRA equipment for critical 
care in severe pneumonia caused by COVID-19 
was represented. It was chosen to exemplify with 
spinraza due to its high budgetary impact, having 
been recently evaluated by CONETEC, making 
recommendations against its coverage at current 
prices, and because these recommendations were 
not taken into account. The comparison with the 
ability to purchase respirators is based on the fact 
that this has been one of the main technologies that 
health systems went out to buy immediately in the 
face of the pandemic, exceeding the available 
supply (12) 12, thus making explicit a homogeneous 
preference for all health decision-makers. This 
comparison is arbitrary, since there are other high-
cost drugs that impact health systems, as well as 
other technologies necessary to cope with the 
pandemic. Those mentioned are selected to show 
theoretical alternatives in a budget line from the 
point of view of an impartial decision-maker who 
must prioritize public resources with a fixed budget. 
Although budgets, by their nature, must be flexible, 
and in the face of the pandemic, most countries 
authorized an increase in the budget for Health, 
they work with a fixed budget based on various 
cons iderat ions,  which inc lude economic 
contraction, inflation and the devaluation of the 
peso-dollar exchange rate (37), as well as 
advantages given by the greater simplicity for the 
analysis.
Spinraza for Spinal Muscular Atrophy
In 2019, 259 patients with different disease 
subtypes and under the responsibility of various 
funders were under treatment with spinraza (32). An 
estimated 100 patients / year with SMA type I under 
treatment with spinraza in Argentina.
In the context of a pandemic where the need for 
respirators becomes a priority for all health 
systems, indifference curves are plotted to illustrate 
the possible decisions when prioritizing between 
respirators and spinraza.
In this exercise, an annual budget set by the cost of 
spinraza -tax-free- is assumed to treat 100 patients / 
year with SMA type 1. Only SMA type 1 is 
considered, because the contrast with severe 
patients with COVID-19 implies units It requires 
equally disappointing forecasts, the interventions of 
which carry a certain likelihood of saving lives in the 
short term. Spinraza would improve MRA-free 
survival or death at 13 months with a Hazard Ratio = 
0.53, suggesting a Number Needed to Treat (NNT) 
of 3.38 patients / year (38). This survival would be 
maintained until at least 32 months of life (39). 
Based on information provided by consultation with 
various funders who are covering treatments in 
Argentina, the tax-free price of spinraza is $ 80,580 
per dose. Six doses are required in the first year, at a 
cost per patient / year of $ 483,448 and $ 
48,348,000 for the estimated 100 patients.
Respirators
In many regions of the United States, Brazil, Chile 
and Peru, the installed capacity of respirators was 
exceeded in the scenario of a COVID-19 pandemic 
(40). In Argentina, estimates of total respirators 
have been reported at 8,560 at the beginning of the 
pandemic, leading to a ratio of 25.5 respirators per 
100,000 inhabitants (41.42). Despite the fact that it 
was later significantly increased, the available 
respirators could be insufficient according to 
different scenarios of the evolution of the pandemic 
(43). Mortality of patients requiring a respirator due 
to COVID ranges from 30 to 80% (44.45). Assuming 
that all serious cases that do not access ARM die, 
and that access to critical care in Argentina reduces 
mortality to 40%, the ventilator would have an NNT 
of 1.72; In other words, for every 1.72 people with 
severe COVID-19 pneumonia who access ARM, 
one life would be saved. The median duration of 
mechanical assistance in the ICU is estimated at 10 
days (10) and, therefore, a ventilator could be used 
in 3 patients per month. For simplicity, in this 
analysis we will consider a single annual peak, 
where each ventilator would be used in only three 
patients. This simplification is conservative, since 
most predictive models show that a single short 
peak is unlikely to occur, and a second peak is 
already underway in Argentina and other countries 
in the region. The price of standard respirators 
available in the Argentine market and in the region is 
USD 20,000 per unit (46). Costs of human 
resources, inputs and indirect costs are not included 
in the analysis.
Results
Under a fixed budget, the choice to cover spinraza 
for the entire estimated population implies losing the 
opportunity to have funds to buy 2 417 extra 
respirators and thus increase Argentina's initial 
installed capacity by 35%.
Given that both technologies would have a potential 
impact on lives saved, the analysis is deepened by 
comparing spinraza and respirators, assuming a 
fixed budget and a scenario in which only these two 
technologies could be financed. In this hypothetical 
situation, if the impartial decision maker had the 
sole objective of maximizing lives saved, he could 
save more than 99% of the lives at stake by 
spending his entire budget on purchasing only 
respirators. This occurs even assuming that each 
respirator was used in only three patients, in a single 
epidemic peak, ignoring that its amortization allows 
it to be used for several years for the benefit of other 
patients with other diseases.
Neoclassical economic theory describes that a 
financier with a fixed budget, when faced with the 
possibility of incorporating different goods, will buy 
those that provide the greatest utility, until reaching 
a point where the marginal profits per monetary unit 
spent on each of the goods are equal. This funder 
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health technologies
Like many countries in the region, Argentina 
combines pre-existing difficulties with new 
challenges related to the pandemic. With a 
fragmented and segmented health system, the 
costs of new technologies are steadily increasing, 
where judicialization for coverage is increasingly 
frequent, finding a fragile balance between demand 
and coverage (15). Given the pandemic, a drop in 
GDP of 11.8% is anticipated for Argentina with a 
rebound of 4.9% in 2021 and for Peru a fall of 13.9% 
in 2020 with a recovery of 7.3% for 2021 (16). While 
urgent needs appear to face COVID, while 
continuing to meet all other health needs not related 
to COVID.
Argentina uses an explicit list of benefits, the 
Obligatory Medical Plan (PMO), as a formal 
reference for the subsector of national social 
security and prepaid medicine companies (41% of 
the population) but which is also referenced by other 
funders such as provincial social works, pensioners 
and retirees social work, and, to a certain extent, the 
public subsector (17). Two thirds of the population 
have formal coverage and the remaining third is 
served exclusively in the public subsector. Total 
investment in health is close to 10% of its GDP (18), 
despite which allocative inefficiencies persist with 
consequences for the overall equity of the system 
(19).
High-cost drugs take a growing percentage of the 
health budget in Argentina as in other countries in 
the region. In Argentina they represent 34% of the 
PMO's total drug spending while in Chile, only three 
orphan drugs prosecuted in 2018 represented 28 
times the annual per-capita budget of the Ricarte 
Soto Law for high-cost diseases (20), and in 
Colombia the coverage of high-cost drugs is 
indicated as one of the causes of the financial health 
crisis (21). In Peru, the Ministry of Health has had 
the Intangible Solidarity Health Fund (FISSAL) 
since 2002, which finances a series of high-cost 
diseases (seven types of most frequent cancers, 
the comprehensive treatment of chronic kidney 
failure and rare and orphan diseases) in people in 
poverty (22,23).
Central strategies to improve efficiency and equity 
in relation to the use of medicines are the evaluation 
of health technologies (HTS) (24) and the regulation 
of medicine prices (25). The countries of the region 
are trying to advance towards the consolidation of 
HTA processes that include evaluations of the 
economic impact and equity (26). The drug price 
regulat ion st rategy,  which has not  been 
implemented in Argentina, unlike other countries in 
the region, such as Brazil, Colombia and Uruguay 
(27), which have various experiences that have 
made it possible to improve the efficiency of their 
drug purchases. WHO-PAHO also recommends 
other strategies, including promoting competition 
either through biosimilars, parallel imports, and 
even incentives for import substitution, modification 
of procurement mechanisms including risk-sharing 
mechanisms, and aggregation of demand to 
through joint negotiation mechanisms and 
consolidated purchases (28).
While in Argentina a National Agency of HTAs still 
awaits to be law (29), the official coverage 
recommendations emanate from an interim official 
commission, the National Commission for Health 
Technology Assessment (CONETEC), created in 
2018, with the aim of “issuing recommendations on 
the incorporation, form of use, financing and / or 
policies for the coverage of health technologies […] 
of a public nature and free consultation for all actors 
in the health system, including judicial processes 
”(30). Its reports are not binding and its 
recommendations are not fully complied with, 
weakening the potential impact of this strategy (31).
This article analyzes the opportunity cost of 
covering sprinaza for Type I Muscular Atrophy 
(SMA) in Argentina. SMA is a hereditary 
neuromuscular disease characterized by the 
involvement of the cells of the anterior horn of the 
spinal cord (motor neurons), which presents with 
symmetric proximal weakness and progressive 
atrophy of the muscle groups. It is a rare disease, 
highly disabling and with high mortality in its most 
serious forms. It has an approximate incidence of 1 
in 6,000 / 10,000 live births, and is the main cause of 
infant mortality due to a genetic disease (32). Four 
forms of presentation of SMA are known, and there 
is evidence that in SMA type I, spinraza reduces 
mortality and the requirement for mechanical 
ventilatory assistance, as well as improves motor 
function, allowing the development and acquisition 
of certain skills (for example sitting, standing, or 
walking) until at least 13 months of observation. It is 
estimated that approximately 100 patients with SMA 
type I receive spinraza in Argentina (32).
Spinraza was not included in the WHO Essential 
Medicines List (33), and despite having a negative 
recommendation by CONETEC (31), it was 
included in the PMO for one year (34,35). Its 
opportunity cost is related to the purchase of 
mechanical ventilation equipment, which has 
become one of the highest priorities in effective and 
safe health technologies to face the pandemic. The 
objective of this study is to illustrate, in this way, the 
impact of high-cost drugs such as spinraza 
(Nusinersen®), and the urgent need to adopt 
strategies to improve efficiency and equity; Among 
them, base decisions on ETES and implement price 
regulation schemes. The context of a pandemic can 
become an opportunity to re-discuss health policies 
related to high-cost drugs, which put the 
sustainability of health systems at risk.
Methodology
The budgetary impact and opportunity cost of 
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In figure 1, the points (Qs and Qr) represent 
interchangeable quantities (patients / year of 
treatment with spinraza and respirators) under a 
fixed budget of slightly less than USD 50 million. 
Indifference curves A and B represent possible 
“preferred” combinations for a decision maker 
interested in equity, not in maximizing lives saved. 
Curve A is inefficient. In B, the decision maker 
interested in maximizing absolute equity “prefers” to 
cover progressively more spinraza or respirators as 
the marginal benefit of an extra unit is relatively 
smaller.
The impact of the cost of spinraza stands out even 
more when the benefit in lives saved is measured. 
Indeed, if a decision-maker with an equity mandate 
wanted to apply 50% of the total budget to each 
technology and health problem, they would buy 
1,209 respirators and cover 50 patients / year with 
spinraza. At this “fair” point, it would stop saving 15 
lives of SMA type 1 patients and 2 108 lives of 
critically ill COVID-19 patients. Most of the 
economic evaluations carried out in other countries 
considered spinraza cost-effective only based on 
discounts greater than 90% (27) 27. As can be seen 
in the following figure, at the current sale price in 
Argentina, even obtaining discounts of up to 95%, 
investing the entire hypothetical budget in spinraza 
would give the opportunity to save 30 lives of SMA 
patients, losing the opportunity to save 211 lives that 
they could potentially be saved by incorporating 
more respirators. In this scenario, made possible by 
discounts, no patient with SMA type 1 would be left 
out of treatment.
In our exercise, the scenario of only treating 100 
carefully selected SMA patients at a 50% discount 
equates to a cost of 2,018 lives of people with 
COVID-19, and each percentage point off the price 
of spinraza would save 44 lives of people with 
COVID-19. In other words, a decision maker who 
agrees to pay for spinraza at a discount of only 50%, 
under the fixed budget of our scenario, is effectively 
valuing each life of a patient with SMA, 70 times 
more than each life of a serious patient with COVID-
19.
Discussion
Pharmaceutical innovation is very important, but the 
cost of new products with proven benefits limits 
access to drugs and other technologies in resource-
limited settings (22). In the case of spinraza for 
patients with SMA type I there would be a potential 
benefit, but the balance between benefits, cost and 
opportunity cost for society must be analyzed in 
depth. The possibility of an improvement in survival 
is something promising that will need to be 
confirmed with new studies and long-term follow-
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will break even when, given your budget and pricing 
constraints, you maximize the profit you make from 
your expenses. Graphically speaking, it will be in 
equilibrium when, given its budget line, it reaches 
the highest indifference curve. The indifference 
curves represent possible combinations preferred 
by a theoretical decision-maker interested in equity, 
not in maximizing lives saved.
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Figure 1: budget line and indifference curves: spinraza versus respirators.
Figure 2: Potential loss of life of seriously ill patients by COVID-19 after the maximum capacity of 
respirators is saturated, according to% discount to the spinraza list price In this simulation, the 
treatment of all patients with SMA type 1 is covered and the remainder of the fixed budget for the 
purchase of respirators is used.
up, but in the meantime, the main problem seems to 
be the price. It is suggested that the price we pay is a 
manifestation of our relative valuation of some 
diseases over others, by will or by judicialization, 
which in the end ends up pointing a market to a 
seller. A society expresses its preferences by 
selecting the interventions it pays, and its 
possibilities in the prices it pays. Various 
publications about the opacity of the drug industry 
value chain (47), as well as the aforementioned 
successful experiences in price regulation, suggest 
that this is a strategy that allows improving access, 
without putting sustainability at risk. of the industry. 
Investment in marketing would double investment in 
research and development, and profit margins are 
higher than in most industries (48). In the region, 
large international differences in the prices of other 
high-cost drugs such as Trastuzumab have already 
been published (49). The difference found between 
the price of spinraza in Argentina and that of Brazil 
(50) is 200%, which confirms that a price regulation 
policy and strategy is necessary to reduce this 
discretion. Brazil used a scheme where the 
regulation of the price of new drugs was related to 
the results of the ETES carried out (27).
Argentina, like other countries in the region, has 
committed itself through international pacts to 
protect the right to health "in accordance with the 
possibilities, organization and resources of the 
State" (51) "... as far as public and community 
resources allow ... ”(52) for the“ ... enjoyment of the 
highest possible level of health ... ”where the 
highest is“ ... according to biological, socio-
economic preconditions and the resources 
available by the State ... ”(53). The right to health 
and life of everyone is equally protected, but the 
appearance of innovative technologies that could 
save lives but have prices such as spinrasa, or even 
higher prices such as zolgensma, which, also for the 
treatment of SMA, it is sold at 2.1 million dollars per 
patient (54), it is evident that it is necessary to have 
binding ETES processes and price regulation, as 
well as a broad social debate. Most of the countries 
in the region show incipient progress in HTA but still 
have significant opportunities for improvement (22) 
22. Despite the negative recommendation of the 
CONETEC ETES, the Argentine Ministry of Health 
included spinraza in the PMO in 2019. A voluntary 
agreement with the seller provided a discount, in 
exchange for funders to cover all forms of SMA. The 
majority did not adhere, calculating an even greater 
budget impact. Recently, the Ministry of Health of 
Argentina terminated this Resolution, incorporating 
a spinraza protected coverage scheme for SMA. In 
January 2021, a new drug for the treatment of SMA 
was registered and approved for commercialization 
in Argentina, it is Onasemnogene abeparvovec 
(Zolgensma®) (55), which at a cost of 2.1 million 
dollars per patient comes to confirm the need for 
National States to raise the need for evaluation, 
regulation and price negotiation.
This research presents among its limitations the 
assumption of the fixed budget and analyze the 
comparison between only two technologies, both 
decisions made for educational purposes. Another 
limitation is having taken the cost of the respirator 
without considering the costs related to supplies 
and human resources. This underestimation is 
probably offset by the conservative assumption that 
a ventilator would be used by only three patients. 
Regarding the comparison of spinraza prices 
between countries, although both are expressed in 
dollars, it may be necessary to adjust these data for 
inflation and purchasing power parity (25).
Argentina, like other countries in the region, must 
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equates to a cost of 2,018 lives of people with 
COVID-19, and each percentage point off the price 
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COVID-19. In other words, a decision maker who 
agrees to pay for spinraza at a discount of only 50%, 
under the fixed budget of our scenario, is effectively 
valuing each life of a patient with SMA, 70 times 
more than each life of a serious patient with COVID-
19.
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cost of new products with proven benefits limits 
access to drugs and other technologies in resource-
limited settings (22). In the case of spinraza for 
patients with SMA type I there would be a potential 
benefit, but the balance between benefits, cost and 
opportunity cost for society must be analyzed in 
depth. The possibility of an improvement in survival 
is something promising that will need to be 
confirmed with new studies and long-term follow-
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manifestation of our relative valuation of some 
diseases over others, by will or by judicialization, 
which in the end ends up pointing a market to a 
seller. A society expresses its preferences by 
selecting the interventions it pays, and its 
possibilities in the prices it pays. Various 
publications about the opacity of the drug industry 
value chain (47), as well as the aforementioned 
successful experiences in price regulation, suggest 
that this is a strategy that allows improving access, 
without putting sustainability at risk. of the industry. 
Investment in marketing would double investment in 
research and development, and profit margins are 
higher than in most industries (48). In the region, 
large international differences in the prices of other 
high-cost drugs such as Trastuzumab have already 
been published (49). The difference found between 
the price of spinraza in Argentina and that of Brazil 
(50) is 200%, which confirms that a price regulation 
policy and strategy is necessary to reduce this 
discretion. Brazil used a scheme where the 
regulation of the price of new drugs was related to 
the results of the ETES carried out (27).
Argentina, like other countries in the region, has 
committed itself through international pacts to 
protect the right to health "in accordance with the 
possibilities, organization and resources of the 
State" (51) "... as far as public and community 
resources allow ... ”(52) for the“ ... enjoyment of the 
highest possible level of health ... ”where the 
highest is“ ... according to biological, socio-
economic preconditions and the resources 
available by the State ... ”(53). The right to health 
and life of everyone is equally protected, but the 
appearance of innovative technologies that could 
save lives but have prices such as spinrasa, or even 
higher prices such as zolgensma, which, also for the 
treatment of SMA, it is sold at 2.1 million dollars per 
patient (54), it is evident that it is necessary to have 
binding ETES processes and price regulation, as 
well as a broad social debate. Most of the countries 
in the region show incipient progress in HTA but still 
have significant opportunities for improvement (22) 
22. Despite the negative recommendation of the 
CONETEC ETES, the Argentine Ministry of Health 
included spinraza in the PMO in 2019. A voluntary 
agreement with the seller provided a discount, in 
exchange for funders to cover all forms of SMA. The 
majority did not adhere, calculating an even greater 
budget impact. Recently, the Ministry of Health of 
Argentina terminated this Resolution, incorporating 
a spinraza protected coverage scheme for SMA. In 
January 2021, a new drug for the treatment of SMA 
was registered and approved for commercialization 
in Argentina, it is Onasemnogene abeparvovec 
(Zolgensma®) (55), which at a cost of 2.1 million 
dollars per patient comes to confirm the need for 
National States to raise the need for evaluation, 
regulation and price negotiation.
This research presents among its limitations the 
assumption of the fixed budget and analyze the 
comparison between only two technologies, both 
decisions made for educational purposes. Another 
limitation is having taken the cost of the respirator 
without considering the costs related to supplies 
and human resources. This underestimation is 
probably offset by the conservative assumption that 
a ventilator would be used by only three patients. 
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between countries, although both are expressed in 
dollars, it may be necessary to adjust these data for 
inflation and purchasing power parity (25).
Argentina, like other countries in the region, must 
187
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(3), july - september: 181-188
Opportunity cost of high-cost medicines and health decisions in times of pandemic186
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(3), july - september: 181-188
Hasdeu S, Lamfre L, Freiberg A
redesign decision-making processes on coverage, 
using the ETES as an input for prioritization with 
binding recommendations, for which it must 
guarantee the competence of the institutions that 
already exist and develop them. The pandemic 
context may be an opportunity to revalue the 
importance of estimating the opportunity cost of 
interventions, especially in the case of high-cost 
drugs. Implementing price negotiation policies, 
which may include risk-sharing agreements or 
discounts ordered from the State, are some of the 
urgent strategies that can help to face the costs of 
the pandemic and continue to cover other health 
needs.
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redesign decision-making processes on coverage, 
using the ETES as an input for prioritization with 
binding recommendations, for which it must 
guarantee the competence of the institutions that 
already exist and develop them. The pandemic 
context may be an opportunity to revalue the 
importance of estimating the opportunity cost of 
interventions, especially in the case of high-cost 
drugs. Implementing price negotiation policies, 
which may include risk-sharing agreements or 
discounts ordered from the State, are some of the 
urgent strategies that can help to face the costs of 
the pandemic and continue to cover other health 
needs.
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Factores asociados a la mortalidad en pacientes hospitalizados por COVID-19: un estudio 
de cohorte
Factors associated with mortality in patients hospitalized by COVID-19: a cohort study
1,#,a 1,$,b 1,$,c 1,%,dSantiago Sánchez-Pardo , Rafael M. Matallana , Lina Ramírez-López , Diana C. Gómez-Pinilla , Sandra 
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Resumen
Introducción: El área de la presente investigación comprende la infección pandémica denominada COVID 
19, según estudios de varios países los factores asociados a presentación grave incluyen: edad superior a 
65 años y comorbilidades como cáncer, asma, hipertensión y enfermedades cardíacas. Objetivo: Describir 
los factores de riesgo asociados a mortalidad en una cohorte de pacientes colombianos hospitalizados por 
COVID 19. Materiales y Métodos: Estudio retrospectivo, observacional, analítico de pacientes 
hospitalizados por COVID 19 que necesitaron uso de oxígeno suplementario y que presentaron marcadores 
inflamatorios elevados o de mal pronóstico, en los servicio de hospitalización y unidad de cuidado intensivo 
en un centro de tercer nivel en Bogotá (Colombia) durante el periodo de marzo a agosto de 2020. Se realizó 
análisis descriptivo y bivariado. Resultados: Se incluyeron 214 pacientes. La edad presentó una media de 
58.2 años con una desviación estándar  15.29. El 60.2% fueron hombres y 39.7% mujeres. El 53.2% 
presentaban antecedentes personales como: Hipertensión arterial 37.8%, diabetes mellitus 21%, 
enfermedad pulmonar obstructiva Crónica 11.6%, infección por VIH 6%. Los factores de riesgo que se 
encontraron relacionados con mortalidad fueron: enfermedad renal crónica (OR 6.68 p=0.002 IC 2.0-22.2), 
diabetes mellitus (OR 4.6 p=0.000 IC 2.2 – 9.6), enfermedad pulmonar obstructiva crónica (OR 4.0 p=0.002 
IC 1.6-9.6) y el género masculino (OR 2.9 p=0.008 IC 1.2 - 6.4). Conclusiones: En Colombia de acuerdo el 
presente estudio se confirma al igual que en otros países la infección por COVID 19 tiene una elevada 
mortalidad a mayor edad y en pacientes con comorbilidades cardiovasculares (enfermedad renal crónica y 
diabetes).
Palabras clave: infecciones por coronavirus; virus del SARS; mortalidad; Enfermedades cardiovasculares 
(Fuente: DECS BIREME).
Abstract
Introduction: The area of  this research includes the pandemic infection called COVID 19, according to 
studies from several countries the factors associated with severe presentation include age over 65 years and 
comorbidities such as cancer, asthma, hypertension and heart disease. Objective: to describe risk factors 
associated with mortality in a cohort of Colombian patients hospitalized for COVID 19. Materials and 
Methods: Retrospective, observational, analytical study of patients hospitalized for COVID 19 who required 
the use of supplemental oxygen and who presented high inflammatory markers or poor prognosis, in the 
Hospitalization and Intensive Care Unit services in a third level center in Bogotá (Colombia) during the period 
from March to August 2020. Results: 214 patients were included. The age presented a mean of 58.2 years 
standard deviation 15.29. 60.2% were men and 39.7% women. 53.2% had personal antecedents such as: 
Hypertension 37.8%, Diabetes mellitus 21%, Chronic obstructive pulmonary disease 11.6%, HIV infection 
6%. The risk factors found to be related to mortality were: chronic kidney disease (OR 6.68 p = 0.002 CI 2.0-
22.2), Diabetes Mellitus (OR 4.6 p = 0.000 CI 2.2 - 9.6), Chronic obstructive pulmonary disease (OR 4.0 p = 
0.002 CI 1.6-9.6) and male gender (OR 2.9 p = 0.008 CI 1.2 - 6.4). Conclusions: In Colombia, according to 
the present study, as in other countries, infection by COVID 19 has a high mortality rate at an older age and in 
patients with cardiovascular comorbidities (chronic kidney disease and diabetes).
Keyword: coronavirus infections, SARS virus, mortality, cardiovascular diseases. (database: DECS 
BIREME).
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Introducción
El área problema de la presente investigación 
comprende las enfermedades infecciosas, 
especialmente la infección pandémica denominada 
COVID 19, (Coronavirus Disease 2019, COVID 19) 
producida por el nuevo coronavirus SARS COV2 
(severe respiratory acute syndrome 2, SARS-CoV-
2) (1-6). La enfermedad fue detectada a finales de 
2019, en pacientes que habían estado expuestos 
posiblemente a transmisión alimentaria desde 
animales salvajes en un mercado de la ciudad 
Wuhan, provincia de Hubei, China, siendo 
reconocida semanas después, en enero del 2020 
(7-8).
La enfermedad es causada por un virus 
(SARSCoV-2), que hace parte de la subfamilia 
Orthocoronavirinae, en el cual se incluyen cuatro 
géneros: Alphacoronavirus, Betacoronavirus, 
Deltacoronavirus y Gammacoronavirus (7-10). El 
género Betacoronavirus, incluye al SARS-CoV-2, y 
a otros dos Betacoronavirus, el SARS-CoV, 
causante de epidemias en 2002-2003 en China y 
otros países dentro y fuera de Asia (del subgénero 
Sarbecovirus) y el Síndrome Respiratorio del Medio 
Oriente (Middle East Respiratory Syndrome, 
MERS-CoV) (del subgénero Merbecovirus) (10).
Los factores de riesgo asociados a un mal 
pronóstico o desenlace clínico desfavorable en 
adultos mayores en Madrid (España) según estudio 
de Mostaza et al. (11) incluyeron mayor edad, 
menor duración de los síntomas antes de la 
hospitalización, frecuencia cardíaca más rápida y 
niveles más altos de proteína C reactiva. Los 
factores asociados a la supervivencia fueron el 
sexo femenino, tratamiento previo con inhibidores 
del sistema renina angiotensina aldosterona 
(RAAS), mayor saturación de oxígeno en urgencias 
y mayor recuento de plaquetas (12-14). En Wuhan 
la ciudad China en donde inicialmente se describió 
la enfermedad se han descrito factores de riesgo 
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